BehaveNet^Ž
Clinical Capsule™

Join Our Mailing List

For Email Newsletters you can trust

drug: oxymorphone

Numorphan^Ž (Endo Pharmaceuticals Inc.) FDA approved indications:
1.28.1959 (injection) relief of moderate to severe pain
4.2.1959 (suppository) relief of moderate to severe pain
U.S. Prescribing information
Opana^Ž (Endo Pharmaceuticals Inc.) FDA approved indications:
6.22.2006 relief of moderate to severe acute pain where the use of an opioid is appropriate
U.S. Prescribing information
Opana^Ž ER (Endo Pharmaceuticals Inc.) FDA approved indications:
6.22.2006 relief of moderate to severe pain in patients requiring continuous, around-the-clock opioid treatment for an extended period of time
U.S. Prescribing information
Opana^Ž Injection (Endo Pharmaceuticals Inc.) FDA approved indications:
10.16.2006 (date of labeling revision: previously marketed as Numorphan^Ž) relief of moderate to severe pain; preoperative medication, for support of anesthesia, and for relief of anxiety in patients with dyspnea associated with pulmonary edema secondary to acute left ventricular dysfunction
U.S. Prescribing information

*Molecule graphic courtesy of Steve Chapman